CLINICAL TRIALS PROFILE FOR VATALANIB

Clinical Trials for Vatalanib

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00056446 ↗	Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer	Completed	Bayer	Phase 3	The purpose of this study is to compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and whose disease has worsened after treatment with irinotecan.
NCT00056446 ↗	Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer	Completed	Novartis Pharmaceuticals	Phase 3	The purpose of this study is to compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and whose disease has worsened after treatment with irinotecan.
NCT00056459 ↗	Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.	Completed	Bayer	Phase 3	To compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and are seeking first chemotherapy treatment
NCT00056459 ↗	Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.	Completed	Novartis	Phase 3	To compare treatment with oxaliplatin/5-FU/leucovorin plus vatalanib versus oxaliplatin/5-FU/leucovorin plus placebo in patients with colorectal cancer that has spread to other organs and are seeking first chemotherapy treatment
NCT00072475 ↗	Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes	Completed	National Cancer Institute (NCI)	Phase 2	RATIONALE: Vatalanib may be effective in preventing the development of leukemia in patients who have myelodysplastic syndromes. PURPOSE: This phase II trial is studying vatalanib to see how well it works in treating patients with primary or secondary myelodysplastic syndromes.
NCT00072475 ↗	Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes	Completed	Alliance for Clinical Trials in Oncology	Phase 2	RATIONALE: Vatalanib may be effective in preventing the development of leukemia in patients who have myelodysplastic syndromes. PURPOSE: This phase II trial is studying vatalanib to see how well it works in treating patients with primary or secondary myelodysplastic syndromes.

Clinical Trial Conditions for Vatalanib

Condition Name

Condition Name
Intervention	Trials
Unspecified Adult Solid Tumor, Protocol Specific	4
Brain and Central Nervous System Tumors	3
Sarcoma	2
Metastatic Neuroendocrine Tumors	2

Condition MeSH

Condition MeSH
Intervention	Trials
Carcinoid Tumor	4
Neoplasms	4
Neuroendocrine Tumors	4
Central Nervous System Neoplasms	3

Clinical Trial Locations for Vatalanib

Trials by Country

Trials by Country
Location	Trials
United States	116
Canada	9
United Kingdom	3
Belgium	3
Germany	3

Trials by US State

Trials by US State
Location	Trials
North Carolina	6
Minnesota	5
Illinois	5
California	5
Louisiana	4

Clinical Trial Progress for Vatalanib

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	2
Phase 2	9
Phase 1/Phase 2	6

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	18
Unknown status	3
Terminated	2

Clinical Trial Sponsors for Vatalanib

Sponsor Name

Sponsor Name
Sponsor	Trials
Novartis	8
National Cancer Institute (NCI)	7
Novartis Pharmaceuticals	5

Sponsor Type

Sponsor Type
Sponsor	Trials
Other	28
Industry	17
NIH	7